SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (49404)1/20/2019 2:25:55 PM
From: weatherproof8 Recommendations

Recommended By
bnutman
diaperdaddy
EMU2
idahoranch1
jargonweary

and 3 more members

  Read Replies (1) of 63326
 
It's just rank speculation to say what SGEN would have or wouldn't have gotten done for this particular therapeutic in this regulatory climate. My understanding is that the SGEN deal for IMMU-132 offered very little beyond the upfront. If we get past what we hope is this last bump in the road, we'll be far better off then we would have been had we given away the crown jewel for peanuts. None of this solves the immediate problem. Let's see what we're looking at first rather than continue with the Monday-morning quarterbacking.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News